• Keine Ergebnisse gefunden

Methodical and clinical investigations using the platelet function analyzer PFA-100 in dogs

The platelet function analyzer PFA-100 proofs the capillary in vitro bleeding time by the blood flow through a capillary. The membrane at the end of the capillary has a central aperture and is covered with the platelet aggregation inducing substance (collagen/ADP or collagen/epinephrine). The closure time and optional the blood volume flowing out of the capillary until closure of the membrane aperture can be determined.

The aim of the study was the testing of the clinical applicability of the platelet function analyzer PFA-100 in dogs. Blood of clinically normal dogs was measured as reference (collagen/ADP-cartridge: n=136; collagen/epinephrine-cartridge: n=128) and various preanalytic studies were done. Additionally, dogs with different diseases which are known to change the platelet function in humans and/ or dogs were examined. These diseases were the von Willebrand disease (n=2), uraemia (n=10), various hepatopathies (n=9) (n=2: liver cirrhosis due to copper hepatotoxicosis; n=2: hepatosis; n=3: degenerative hepatopathy;

n=1: liver metastases of a tumour; n=1: hepatitis); portosystemic shunts (n=10), leishmaniasis (n=12); acute lymphatic leukaemia (n=7), chronic lymphatic leukaemia (n=4), lymphosarcoma (n=9) and multiple myeloma (n=4). Dogs with hyperfibrinolysis as a result of metastatic carcinomas were tested (n=8). To prove the influence of acetylsalicylic acid on the primary haemostasis of the dog acetylsalicylic acid was given to clinically normal dogs. Acetylsalicylic acid was added to blood samples of healthy dogs as well. 39 samples of 32 dogs with thrombocytopenia (platelet count < 150.000/µl) of various causes and with haematocrit values > 30 % were examined. The specificity of the platelet function analyzer PFA-100 was assessed in dogs with coagulopathies (coumarin intoxication: n=8; haemophilia A: n=3).

Reference range using the collagen/ADP-cartridge was 53 - 98 seconds (median:

73 seconds) for the closure time and 227 - 318 µl (median: 264 µl) for the blood volume. The reference range using the collagen/epinephrine-cartridge was 92 -

>300 seconds (median: 163 seconds) for the closure time, which reaches the maximum of measurement range (300 seconds), and 296 - 720 µl (median: 414 µl) for the blood volume. The reference range of in vivo bleeding time was 60 -

150 seconds for capillary bleeding and 45 - 90 seconds for subaquale bleeding time.

For precision study in series, median variation coefficients of 7.3 % (closure time) and 2.7 % (blood volume), respectively, were found.

Comparing six different collagen/ADP-cartridge-lot numbers neither the closure time (p=0.1548, ANOVA) nor the blood volume (p=0.0921, ANOVA) was significantly different.

The time of sample storage until measurement (0-24 h) did not influence the closure time (p=0.0842, ANOVA) or the blood volume (p=0.0655) using the collagen/ADP-cartridge. Global statistical comparison by Friedman-test revealed clear differences between times for the closure time (p=0.0120) and blood volume (p=0.0061) using the collagen/epinephrine-cartridge. The local comparison with the Wilcoxon-test showed an increase of closure time at 24-h-storage compared to the 1-h-value.

Blood samples of various levels of haematocrit (collagen/ADP-cartridge) showed significant differences. The decrease of the haematocrit from 40 % to 30% resulted in a clear increase of the closure time (p=0.0049, t-test) and the blood volume (p=0.0030, t-test).

Based on the blood samples of thrombocytopenic and healthy dogs platelet number was closer correlated to the closure time (dogs with thrombocytopenia:

r = - 0.5793; total number of dogs: r = - 0.3991), or the blood volume (dogs with thrombocytopenia: r = - 0.5493; total number of dogs: r = - 0.4340) using the collagen/ADP-cartridge in comparison to the collagen/epinephrine-cartridge. In the group of dogs with thrombocytopenias the correlation between the capillary bleeding time or subaquale bleeding time and the results of PFA-100 was closer using the collagen/ADP-cartridge than using the collagen/epinephrine-cartridge.

After in vivo and in vitro application of acetylsalicylic acid the measurements with the collagen/epinephrine-cartridge showed a pronounced increase of closure time and blood volume. With the collagen/ADP-cartridge the increase was less remarkable.

Particularly the results of dogs with uraemia, leishmaniasis and multiple myeloma indicated platelet function disorders. The interpretation of the automated measurements of platelet function was difficult with diseases

showing thrombocytopenia and anemia. The blood samples of dogs with portosystemic shunts were all within the reference range.

The results of dogs with coagulopathies correspond to the median closure time and the median blood volume of the control group.

The platelet function analyzer PFA-100 detected thrombocytopenias, the acetylsalicylic acid induced thrombocytopathia, different thrombocytopathias and the von Willebrand disease. Moreover the platelet function analyzer had a high specificity to disorders of primary haemostasis. However, because of the influence of the haematocrit, its clinical usability is clearly reduced.

H. Literaturverzeichnis ADAMIK, A., u. R. MISCHKE (1998):

Einfluß des Auswertungsverfahrens auf die Sensitivität der Resonanzthrombographie bei der Thrombozytopenie des Hundes.

Dtsch. Tierärztl. Wochenschr. 105, 405-407

AGAM, G., A. GUTMAN u. M. DJALDETTI (1977):

Abnormal platelet glycogen metabolism in multiple myeloma patients.

Clin. Chim. Acta 79, 437-445

ALESKOG, A.E., A. KILLANDER, K. OLSSON, L. ERIKSSON u. J.

KRISTENSEN (1995):

Preoperative evaluation of primary hemostasis in patients with thrombocytopenia using the Thrombostat 4000.

Semin. Thromb. Hemost. 21 (Suppl. II), 59-65 ALSHAMEERI, R.S., u. E.F. MAMMEN (1995):

Clinical experience with the Thrombostat 4000.

Semin. Thromb. Hemost. 21 (Suppl. II), 1-10 AMMELOUNX, U., u. I. NOLTE (1987):

Untersuchung zur Wirksamkeit von Kortison bei gesunden Hunden mit physiologischen Thrombozytenzahlen, aspirininduzierten Blutungszeit-verlängerungen und bei Hunden mit thrombozytopenischen Krankheitsbildern.

Berl. Münch. Tierärztl. Wochenschr. 100, 124-129

ANDERS, O., B. ERNST, G. HESS, H. KONRAD, V. LAKNER u. M.

SEYFARTH (1985):

Die Beurteilung der klinischen Effektivität der Thrombozytensubstitution bei akuter Leukämie mit der Resonanzthrombographie.

Folia Haematol. 112, 587-593

ASTRUP, T., u. S. THORSEN (1972):

The physiology of fibrinolysis.

Med. Clin. North Am. 56, 153-162

BALLARD, H.S., u. A.J. MARCUS (1976):

Platelet aggregation in portal cirrhosis.

Arch. Intern. Med. 136, 316-319

BARR, S.C., J.W. LUDDERS, A.L. LOONEY, R.D. GLEED u. H.N. ERB (1992):

Platelet aggregation in dogs after sedation with acepromazine and atropine and during subsequent general anesthesia and surgery.

Am. J. Vet. Res. 53, 2067-2070

BECK, K.-H., U. BLECKMANN, P. MOHR u. V. KRETSCHMER (1995a):

DDAVP`s shortening of the bleeding time seems due to plasma von Willebrand factor.

Semin. Thromb. Hemost. 21 (Suppl. II), 40-43

BECK, K.-H., P. MOHR, U. BLECKMANN, H. SCHWEER u. V.

KRETSCHMER (1995b): Desmopressin effect on acetylsalicylic acid impaired platelet function.

Semin. Thromb. Hemost. 21 (Suppl. II), 32-39

BERTOLINO, G., P. NORIS u. C.L. BALDUINI (1991):

Qualitative and quantitative platelet defect with bleeding symptoms as presenting feature of non Hodgkin lymphomas.

Haematologica 76, 243-244 BICK, R.L. (1985):

Disseminated intravascular coagulation and related syndromes.

In: R.L. BICK (Hrsg.):

Disorders of hemostasis and thrombosis. Principles of Clinical Practice.

Verlag Thieme, Stuttgart, New York, 157-204 BICK, R.L. (1992):

Platelet function defects: a clinical review.

Semin. Thromb. Hemost. 18, 167-185

BINHAZIM, A.A., W.L. CHAPMAN, K.S. LATIMER, M. STYLES u. K.

COMER (1992):

Canine leishmaniasis caused by Leishmania leishmania infantum in two Labrador retreivers.

J. Vet. Diagn. Invest. 4, 299-305

BLOCKMANS, D., H. DECKMYN u. J. VERMYLEN (1995):

Platelet activation.

Blood Rev. 9, 143-156

BÖCK, M., J. DE HAAN, K.-H. BECK, K. GUTENSOHN, H.-J.

HERTFELDER, R. KARGER, M. U. HEIM, H. BEESER, D. WEBER u. V.

KRETSCHMER (1999): Standardization of the PFA-100 platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives.

Br. J. Haematol. 106, 898-904

BÖCK, M., J. GROH, A. GLASER, K. STORCK, M.A.A. KRATZER u. M.U.

HEIM (1995):

Quality control of platelet concentrates by the Thrombostat 4000.

Semin. Thromb. Hemost. 21 (Suppl. II), 91-95

BÖHNER, J., K.-W. VON PAPE, W. WIEBERSINSKY, E. ALAND?, M.

WUTTKE u. R. DÖLP (1997):

Serial assessment of platelet function following a single 300 mg dose of acetylsalicylic acid.

Ann. Hematol. 74 (Suppl. II), A136 (Abstr.) BORN, G.V.R. (1962):

Aggregation of blood platelets by adenosine diphosphate and its reversal.

Nature 194, 927-929.

BORRIES, M., D. SÖHNGEN, CH. ENGLISCH, F.C. SCHOEBEL, D. STEIN, H. STIEGLER, CH. BOOGEN, BE. STRAUER u. M. LESCHKE (1997):

Measurement of the effect of aspirin and ticlopidin on platelet function with a simple in vitro bleeding test.

Ann. Hematol. 74 (Suppl. II), A137 (Abstr.)

BORZINI, P., A. LAZZARO u. L. MAZZUCCO (1999):

Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100).

Haematologica 84, 1104-1109

BOUDREAUX, M.K., C. CRAGER, A.R. DILLON, K. STANZ u. M. TOIVIO-KINNUCAN (1994):

Identification of an intrinsic platelet function defect in Spitz dogs.

J. Vet. Int. Med. 8, 93-98

BOUDREAUX, M.K., K. KVAM, A.R. DILLON, C. BOURNE, M. SCOTT, K.A. SCHWARTZ u. M. TOIVIO-KINNUCAN (1996a):

Type I Glanzmann`s Thrombasthenia in a Great Pyrenees dog.

Vet. Pathol. 33, 503-511

BOUDREAUX, M.K, V.S. PANANGALA u. C. BOURNE (1996b):

A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen.

Vet. Pathol. 33, 419-427

BOWEN, D.J., R.M. CLEMMONS, D.J. MEYER u. M.R. DORSEY-LEE (1988):

Platelet functional changes secondary to hepatocholestasis and elevation of serum bile acids. Thromb. Res. 52, 649-654

BRASSARD, J.A. u. K.M. MEYERS (1994):

Von Willebrand factor is not altered in azotemic dogs with prolonged bleeding times.

J. Lab. Clin. Med. 124, 55- 62

BRASSARD, J.A., K.M. MEYERS, M. PERSON u. C.R. DHEIN (1994):

Experimentally induced renal failure in the dog as an animal model of uremic bleeding.

J. Lab. Clin. Med. 124, 48-54 BROOKS, M. (1992):

Management of canine von Willebrand`s disease.

Probl. Vet. Med. 4, 636-646

BROOKS, M., u. J. CATALFAMO (1993):

Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders.

Thromb. Haemost. 70, 777-780

CARCAO, M.D., V.S. BLANCHETTE, J.A. DEAN, L. HE, M.A. KERN, A.M.

STAIN u. C.R. SPARLING (1998):

The platelet function analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children.

Br. J. Haematol. 101, 70-73

CARCAO, M.D., J. DEAN, L. HE, A.M. STAIN, C.R. SPARLING, H.

CHRISTENSEN, J. FREEDMAN, V.S. BLANCHETTE u. M.L. RAND (1997):

Evaluation of platelet function in a pediatric setting using the platelet function analyzer (PFA-100).

Thromb. Haemost. 78 (Suppl), PS-300 (Abstr.) CARDINAL, D.C., u. R.J. FLOWER (1980):

The electronic aggregometer: a novel device for assessing platelet behaviour in blood.

J. Pharmacol. Meth. 3, 135-158

CASTILLO, R., T. LOZANO, G. ESCOLAR, L. REVERT, J. LOPEZ u. A.

ORDINAS (1986):

Defective platelet adhesion on vessel subendothelium in uremic patients.

Blood 68, 337-342

CATTANEO, M., A. B. FEDERICI, A. LECCHI, B. AGATI, R. LOMBARDI, F. STABILE u. P. BUCCIARELLI (1999a):

Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.

Thromb. Haemost. 82, 35-39

CATTANEO, M., A. LECCHI, B. AGATI, R. LOMBARDI u. M.L. ZIGHETTI (1999b):

Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion.

Thromb. Res. 96, 213-217

CAZENAVE, J.P., M.A. PACKHAM u. J.F. MUSTARD (1973):

Adherence of platelets to a collagen-coated surface: development of a quantitative method.

J. Lab. Clin. Med. 82, 978-990

CHANG, A.C., H. JACOBS, M.J. WEINSTEIN U. C.M. KESSLER (1998):

The correlation of closure time and von Willebrand factor activity of factor VIII concentrates.

Blood 92 (Suppl. II), 184a (Abstr.)

CLANCY, R., E. JENKINS u. B. FIRKIN (1972):

Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura.

N. Engl. J. Med. 286, 622-626

COLLEN, D., u. H.R. LIJNEN (1995).

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.

Thromb. Haemost. 74, 167-171

COMP, P., E. LARKIN, R. GOSSELIN, C. GREENBERG, K. HOOTS, C.

KESSLER, D. LILES, E. MAMMEN u. D. NUGENT (1997):

PFA-100 system: A new method for assessment of platelet dysfunction.

Thromb. Haemost. 78 (Suppl), PS-298 (Abstr.) COUTO, C.G. (1985):

Clinicopathologic aspects of acute leukemias in the dog.

J. Am. Vet. Med. Assoc. 186, 681-685

COWAN, D.H., R.C. GRAHAM u. D. BAUNACH (1975):

The platelet defect in leukemia.

J. Clin. Invest. 56, 188-200

DAVENPORT, D.J., E.B. BREITSCHWERDT u. M.C. CARAKOSTAS (1982):

Platelet disorders in the dog and cat. Part I: Physiology and pathogenesis.

Compend. Contin. Educ. Pract. Vet. 4, 762-772

DAVIS, J.W., J.R. McFIELD, P.E. PHILLIPS u. B.A. GRAHAM (1972):

Guanidinosuccinic acid on human platelet effects of exogenous urea, creatinine, and aggregation in vitro.

Blood 39, 388-397

DAVIS, R.B., A. THEOLOGIDES u. B.J. KENNEDY (1969):

Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases.

Ann. Int. Med. 71, 67-80

DEAN, J.A., V.S. BLANCHETTE, M.D. CARCAO, A.M. STAIN, C.R.

SPARLING, J. SIEKMANN, P.L. TURECEK, D. LILLICRAP u. M.L. RAND (2000):

Von Willebrand disease in a pediatric-based population - comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.

Thromb. Haemost. 84, 401-409

DE GROOT, P., u. J.J. SIXMA (1990):

Platelet adhesion.

Br. J. Haematol. 75, 308-312

DE HAAN, J., u. H.-J. KOLDE (1996):

Determination of the primary hemostasis potential of whole blood with PFA-100.

Ann. Hematol. 72 (Suppl. I), A69 (Abstr.) DI BARTOLA, S.P., u. D.J. MEUTEN (1980):

Renal amyloidosis in two dogs presented for thromboembolic phenomena.

J. Am. Anim. Hosp. Assoc. 16, 129-135

DI PAOLA, J., A.B. FEDERICI, P.M. MANNUCCI, M.T. CANCIANI, M.

KRITZIK, T.J. KUNICKI u. D. NUGENT (1999):

Low platelet a2b1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system.

Blood 93, 3578-3582

DIETRICH, G., V. KRETSCHMER u. D. ORTH (1990a):

Primary hemostasis in hemodilution.

Blut 60, 132 (Abstr.)

DIETRICH, G., V. KRETSCHMER, D. ORTH u. W. HAUPT (1990b):

Primary hemostasis in hemodilution - 1) Hematocrit.

Infusionsther. 17, 212-213

DIETRICH, G., V. KRETSCHMER, B. SCHIKOR u. D. SÖHNGEN (1990c):

Der In-vitro-Blutungstest (IVBT) - Eine empfindliche Methode zum Nachweis von Plättchenfunktionsstörungen bei Thrombozytenspendern.

Beitr. Infusionsther. 26, 142-146

DIETRICH, G.V., V. KRETSCHMER, D. WEBER, W. HAUPT, B. LANGEN u. B. HUSS (1995a):

Variables influencing the Thrombostat 4000. Recommended standardization.

Sem. Thromb. Hemost. 21 (Suppl. II), 11-19

DIETRICH, G., D. ORTH, W. HAUPT u. V. KRETSCHMER (1990d):

Primary hemostasis in hemodilution - 2) Infusion solutions.

Infusionsther. 17, 214-216

DIETRICH, G.V., D. SÖHNGEN u. V. KRETSCHMER (1995b):

Therapeutic use of phospholipids in thrombocytopenic and thrombocytopathic patients.

Sem. Thromb. Hemost. 21 (Suppl. II), 77-78

DI MINNO, G., F. CORAGGIO, A. M. CERBONE, A.M. CAPITANIO, C.

MANZO, M. SPINA, P. SCARPATO, G.M.R. DATTOLI, P.L. MAATIOLI u.

M. MANCINI (1986):

A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.

J. Clin. Invest. 77, 157-164

DI MINNO, G., J. MARTINEZ, M.-L. MCKEAN, J. DE LA ROSA, J.F.

BURKE u. S. MURPHY (1985):

Platelet dysfunction in uremia.

Am. J. Med. 79, 552-559 DUKE, W.W. (1910):

The relation of blood platelets to hemorrhagic diseases: Descriptio n of method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion.

J. Am. Med. Assoc. 55, 1185-1192

EBERST, M.E., u. L.R. BERKOWITZ (1994):

Hemostasis in renal disease: pathophysiology and management.

Am. J. Med. 96, 168-179

ESCOLAR, G., A. CASES, E. BASTIDA, M. GARRIDO, J. LOPEZ, L.

REVERT, R. CASTILLO u. A. ORDINAS (1990):

Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoproetin IIb-IIIa.

Blood 76, 1336-1340

ESCOLAR, G., A. CASES, M. VINAS, M. PINO, J. CALLS, I. CIRERA u. A.

ORDINAS (1999):

Evaluation of acquired platetelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.

Haematologica 84, 614-619

EY, F.S. u. S.H. GOODNIGHT (1990):

Bleeding disorders in cancer.

Semin. Oncol. 17, 187-197

FAVALORO, E.J., D. FACEY u. A. HENNIKER (1999):

Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand`s disease and other disorders.

Am. J. Hematol. 62, 165-174

FELDMAN, B.F., K.J. THOMASON u. N.C. JAIN (1988):

Quantitative platelet disorders.

Vet. Clin. North Am. Small Anim. Pract. 18, 35-49 FERRER, L. (1994):

Terapeutica Veterinaria de Pequenos Animales. Vol. XI. Eds. R.W. Kirk, J.D.

Bonagura. New York, Interamericana-McGraw-Hill. P. 296.

zit. nach P. MORENO (1998)

FEURING, M., K. HASEROTH, C.P. JANSON, E. FALKENSTEIN, B.M.W.

SCHMIDT, u. M. WEHLING (1999):

Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100).

Int. J. Clin. Pharmacol. Ther. 37, 584-588

FONT, A., C. GINES, J.M. CLOSA u. J. MASCORT (1994):

Visceral leishmaniasis and disseminated intravascular coagulation in a dog.

J. Am. Vet. Med. Assoc. 204, 1043-104

FORSYTHE, L.T., M.L. JACKSON u. S.M. MERIC (1989):

Whole blood platelet aggregation in uremic dogs.

Am. J. Vet. Res. 50, 1754-1757 FOX, J.E.B. (1993):

The platelet cytoskeleton.

Thromb. Haemost. 70, 884-893.

FRANCIS, J., D. FRANCIS, L. LARSON, E. HELMS u. M. GARCIA (1999):

Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice ?

Platelets 10, 132-136

FRENCH, A.J., u. J.S. LILLEYMAN (1979):

Bleeding tendency of T-cell lymphoblastic leukemia.

Lancet 2 (8140), 469-470

FRESSINAUD, E., A. VEYRADIER, M. SIGAUD, C. BOYER-NEUMANN, C. LE BOTERFF u. D. MEYER (1999) :

Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyzer at high shear rates.

Brit. J. Haematol. 106, 777-783

FRESSINAUD, E., A. VEYRADIER, F. TRUCHAUD, I. MARTIN, C.

BOYER-NEUMANN u. D. MEYER (1996):

High sensitivity of the platelet function analyzer (PFA-100) for the screening of patients with von Willebrand disease: A study of twenty-six cases.

Haemophilia 2 (Suppl. II), 96 (Abstr.)

FRESSINAUD, E., A. VEYRADIER, F. TRUCHAUD, I. MARTIN, C.

BOYER-NEUMANN, M. TROSSAERT u. D. MEYER (1998):

Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases.

Blood 91, 1325-1331

FRESSINAUD, E., A. VEYRADIER, M. TROSSAERT, F. TRUCHAUD, M.

WOLF u. D. MEYER (1997):

Screening and control of therapy of patients with von Willebrand disease using a new analyzer of platelet function under high shear stress.

Thromb. Haemost. 78 (Suppl), PS-2838 (Abstr.) GAWAZ, M.P. (1999):

2. Thrombozyten und primäre Hämostase. 5. Funktionsdiagnostik.

In: M. GAWAZ (Hrsg.):

Das Blutplättchen.

Verlag Thieme, Stuttgart, New York, 4-24, 42-53 GENTRY, P.A. (2000):

Platelet biology.

In: B.F. FELDMAN, J.G. ZINKL u. N.C. JAIN (Hrsg.):

Schalm´s veterinary hematology. 5. Aufl.

Verlag Lippincott Williams & Wilkins, Philadelphia, Baltimore, 459 - 466 GEORGE, J.N. (1972):

Direct assessment of platelet adhesion to glass: a study of the forces of interaction and the effects of plasma and serum factors, platelet function and modification of the glass surface.

Blood 40, 862-874

GEORGE, J.N., u. A.T. NURDEN (1994):

Inherited disorders of the platelet membrane: Glanzman thrombasthenia, Bernard-Soulier syndrome and other disorders.

In: R.W. COLMAN, J. HIRSH, V.J. MARDER u. E.W. SALZMAN (Hrsg.):

Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3. Aufl.

Verlag Lippincott, Philadelphia, 652-672

GERRARD, J.M., S.F. STODDARD, R.S. SHAPIRO, P.F. COCCIA, N.K.C.

RAMSAY, M.E. NESBIT, G.H.R. RAO, W. KRIVIT u. J.G. WHITE (1978):

Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia.

Br. J. Haematol. 40, 597-607 GLASPY, J.A. (1992):

Disturbances in hemostasis in patients with B-cell malignancies.

Semin. Thromb. Hemost. 18, 440-448

GORDGE, M.P., R.W. FAINT, P.B. RYLANCE u. G.H. NEILD (1988):

Platelet function and the bleeding time in progressive renal failure.

Thromb. Haemost. 60, 83-87

GRAUER, G.F., B.J. ROSE, L. TOOLAN, M.A. HULL THRALL u. S.P.

COLGAN (1992):

Effects of low-dose aspirin and specific thromboxane synthetase inhibition on whole blood platelet aggregation and adenosine triphospate secretion in healthy dogs.

Am. J. Vet. Res. 53, 1631-1635

GRALNICK, H.R., S. MARCHESI u. H. GIVELBER (1972):

Intravascular coagulation in acute leukemia: clinical and subclinical abnormalities.

Blood 40, 709-718

GREEN, R.A., u. A.L. KABEL (1982):

Hypercoagulable state in three dogs with nephrotic syndrome: role of acquired antithrombin III deficiency.

J. Am. Vet. Med. Assoc. 181, 914-917 GRINDEM, C.B. (1996):

Blood cell markers.

Vet. Clin. North Am. Small Anim. Pract. 26, 1043-1064

GRINDEM, C.B., E.B. BREITSCHWERDT, W.T. CORBETT u. H.E. JANS (1991):

Epidemiologic survey of thrombocytopenia in dogs: a report on 987 cases.

Vet. Clin. Pathol. 20, 38-43

GRINDEM, C.B., E.B. BREITSCHWERDT, W.T. CORBETT, R.L. PAGE u.

H.E. JANS (1994):

Thrombocytopenia associated with neoplasia in dogs.

J. Vet. Int. Med. 8, 400-405

GUARINI, A., M. BACCARANI, G. CORBELLI, L. GUGLIOTTA u. S.

TURA (1980):

Defibrination in adult acute lymphoblastic leukaemia.

Nouv. Rev. Fr. Hématol. 22, 115-123 zit. nach R. MISCHKE (1998b)

HAMMER, A.S., u. C.G. COUTO (1994):

Complications of multiple myeloma.

J. Am. Anim. Hosp. Assoc. 30, 9-14

HARKER, L.A., u. S.J. SLICHTER (1972):

The bleeding time as a screening test for evaluation of platelet function.

N. Engl. J. Med. 287, 155-159

HARRIS, C.L. u. D.R. KRAWIEC (1990):

The pathophysiology of uremic bleeding.

Compend. Contin. Educ. Pract. Vet. 12, 1294-1298

HARRISON, P., M.S.C. ROBINSON, I.J. MACKIE, J. JOSEPH, S.J.

MCDONALD, R. LIESNER, G.F. SAVIDGE, J. PASI u. S.J. MACHIN (1999):

Performance of the platelet function analyzer PFA-100® in testing abnormalities of primary haemostasis.

Blood Coagul. Fibrinolysis 10, 25-31 HARTERT, H. (1981):

Resonance-thrombographie, theoretical and practical elements.

Biorheology 18, 693-701 HARTERT, H. (1983):

Differenzierung der Therapie von Gerinnungsstörungen mit dem Resonanzthrombographen.

Therapiewoche 33, 4626-4634

HEILMANN, E.J., S.K. KUNDU, R. SIO, C. GARCIA, R. GOMEZ u. D.J.

CHRISTIE (1997):

Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system.

Thromb. Res. 87, 159-164 HELFAND, S.C. (1988):

Platelets and neoplasia.

Vet. Clin. North Am. Small Anim. Pract. 18, 131-156 HELLEM, A.J. (1960):

The adhesiveness of human blood platelets in vitro.

Scand. J. Clin. Lab. Invest. Suppl. 51, 12-56

HEMKER, H.C., u. H. POLIWODA (1997):

Theoretische Voraussetzungen.

In: M. BARTHELS u. H. POLIWODA (Hrsg.):

Gerinnungsanalysen. 5. Aufl.

Verlag Thieme, Stuttgart, New York, 1-20

HENRY, C.J., A. LANEVSCHI, S.L. MARKS, J.C. BEYER, S.H.

NITSCHELM u. S. BARNES (1996):

Acute lymphoblastic leukemia, hypercalcemia, and pseudohyperkalemia in a dog.

J. Am. Vet. Med. Assoc. 208, 237-239

HEYNS, A. DU P., J. FRASER u. F.P. RETIEF (1978):

Platelet aggregation in chronic idiopathic thrombocytopenic purpura.

J. Clin. Pathol. 31, 1239-1243

HÉZARD, N., D. METZ, P. NAZEYROLLAS, C. DROULLE, J. ELAERTS, G.

POTRON u. P. NGUYEN (2000):

Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents.

Thromb. Haemost. 83, 540-544 HILLER, E., u. T. SCHAAL (1981):

Der Einfluß der Thrombozyten auf das Resonanzthrombogramm (RTG).

in: G. BLÜMEL u. S. HAAS (Hrsg.):

Mikrozirkulation und Prostaglandinstoffwechsel; Interaktion von Blutgerinnung und Fibrinolyse mit anderen proteolytischen Enzymsystemen; Neues über Fibrinogen, Fibrin und Fibrinkleber.

Verhandl.ber. d. 25. Tagung d. Dtsch. Arbeitsgem. f. Blutgerinnungsforschung, München, Februar 1981, S. 487-491

HILLER, E., B. REINHRADT, T. BINSACK u. H. RIESS (1982):

Möglichkeiten und Grenzen der Resonanzthombographie (RTG).

in: Verhandl.ber. d. 2. Kongr. f. Thrombose u. Blutgerinnung, Münster, Februar 1982, Stuttgart, Schattauer Verlag, S. 768-771

HOFFMANN, J., G. BONACKER, V. KRETSCHMER, T. SCHULZKI u. J.

HEIMANNS (1996):

IVBT- documented platelet function correlates with flow cytometric data.

Transfus. Sci. 17, 553-558

HÖGMAN, C.F., L. ERIKSSON u. J. KRISTENSEN (1993):

Leukocyte-depleted plateles prepared from pooled buffy coat post-transfusion increment and "in vitro bleeding time" using the Thrombostat 4000/2.

Transfus. Sci. 14, 35-39

HOMONCIK, M., B. JILMA, N. HERGOVICH, P. STOHLAWETZ, S.

PANZER u. W. SPEISER (2000):

Monitoring of Aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.

Thromb. Haemost. 83, 316-321

HORROWITZ, H.I., B.D. COHEN, P. MARTINEZ u. M.F. PAPAYOANOU (1967): Defective ADP-induced platelet factor 3 activation in uremia.

Blood 30, 331-340

JACOBSSON, B., L. RANSNÄS, G. NYBERG, C.-H. BERGH, Y.

MAGNUSSON u. A. HJALMARSON (1985):

Abnormality of adenylate cyclase regulation in human platelet membranes in renal insufficiency.

Eur. J. Clin. Invest. 15, 75-81 JAIN, N.C. (1975):

The platelets: structural, biochemical, and functional aspects.

In: N.C. Jain (Hrsg.):

Schalm`s veterinary hematology. 4. Aufl.

Verlag Lea & Febiger, Philadelphia, S. 446-465 JAIN, N.C. (1993):

The platelets.

In: N.C. Jain (Hrsg.):

Essentials of veterinary hematology.

Verlag Lea & Febiger, Philadelphia, S. 105-132

JERGENS, A.E., M.A. TURRENTINE, K.H. KRAUS u. G.S. JOHNSON (1987):

Buccal muosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand`s disease.

Am. J. Vet. Res. 48, 1337-1342.

JUBELIRER, S.J., F. RUSSEL, R. VAILLANCOURT u. D. DEYKIN (1980):

Platelet arachidonic metabolism and platelet function in ten patients with chronic myelogenous leukemia.

Blood 56, 728-731

KARGER, R., K. GUTENSOHN, M. BÖCK, K.-H. BECK, K.-H.

HERTFELDER u. V. KRETSCHMER (1997):

PFA-100 closure time. Reference range for blood in 3.2% buffered citrate.

Infusionsther. Transfusionsmed. 24, 303 F/G-442 (Abstr.) KASTURI, J., u. A.K. SARAYA (1978):

Platelet functions in dysproteinaemia.

Acta Haematol. 59, 104-113

KATZATCHKINE, M., Y. SULTAN, J.P. CAEN u. J. BARIETY (1976):

Bleeding in renal failure: a possible cause.

BMJ 2, 612-615

KAUFMANN, J.E., A. OKSCHE, C.B. WOLLHEIM, G. GÜNTHER, W.

ROSENTHAL u. U.M. VISCHER (2000):

Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

J. Clin. Invest. 106, 107-116

KLEIN, A., A. ADAMIK u. R. MISCHKE (1999):

Lagerungsbedingte Veränderungen im Thrombozytenkonzentrat des Hundes.

Teil I: Zahl und In-vitro-Funktionsfähigkeit der Thrombozyten. Teil II:

Biochemische Veränderungen im Konzentratplasma.

Berl. Münch. Tierärztl. Wochenschr. 112, 243-253; 281-288

KOTTKE-MARCHANT, K., J. POWERS u. L. BROOKS (1997):

Inhibition of platelet function with ReoPro (abciximab) detected by platelet function analyzer (PFA-100) in patients undergoing coronary angioplasty (PTCA).

Blood 90 (Suppl. I), 70b (Abstr.)

KOTTKE-MARCHANT, K., J.B. POWERS, L. BROOKS, S. KUNDU u. D.J.

CHRISTIE (1999):

The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).

Clin. Appl. Thromb. Hemost. 5, 122-130

KRATZER, M.A.A. u. G.V.R. BORN (1985):

Simulation of primary haemostasis in vitro.

Haemostasis 15, 357-362

KRATZER, M.A.A., S. BELLUCCI u. J.P. CAEN (1985):

Detection of abnormal platelet functions with an in vitro model of primary haemostasis. Haemostasis 15, 363-370

KRATZER, M.A.A., E.V. NEGERSCU, A. HIRAI, Y.K. YEO, P. FRANKE u.

W. SIESS (1995):

The Thrombostat system: A useful method to test antiplatelet drugs and diets.

Semin. Thromb. Hemost. 21 (Suppl. II), 25-31

KRATZER, M.A.A., K. STORCK u. J. GROH (1997):

Prediction of the transfusion effect of platelet concentrates as measured by a model of primary hemostasis ex vivo.

Haemostasis 27, 99-104

KRETSCHMER, V., B. HUSS, G. BONACKER, J. HOFFMANN, S.

BEWARDER, S. WEBER, T. SCHULZKI, H. KÖPPLER u. J. HEIMANNS

BEWARDER, S. WEBER, T. SCHULZKI, H. KÖPPLER u. J. HEIMANNS